New COPD Maintanence Treatment Striverdi Respimat (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies
RIDGEFIELD, CONN. - October 8, 2014 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 µg is now available by prescription in pharmacies across the U.S. The U.S. Food and Drug Administration (FDA) approved STRIVERDI RESPIMAT in July 2014 as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Boehringer Ingelheim will offer a savings card that will allow most eligible patients to get STRIVERDI RESPIMAT at no cost for a limited time, depending on their insurance provider. The savings card is available at www.STRIVERDI.com and can be activated at any pharmacy. For more information about Boehringer Ingelheim’s patient assistance program, BI Cares, please visit BIPatientAssistance.com.
Read the full press release here.